NasdaqGS - Nasdaq Real Time Price USD

Mineralys Therapeutics, Inc. (MLYS)

Compare

12.34

+0.51

(+4.31%)

At close: December 20 at 4:00:02 PM EST

12.34

0.00

(0.00%)

After hours: December 20 at 4:13:32 PM EST

Mineralys Therapeutics Announces Q3 2024 Results and Updates

Mineralys Therapeutics, Inc. ( (MLYS) ) has released its Q3 earnings. Here is a breakdown of the information Mineralys Therapeutics, Inc. presented to its investors. Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on developing treatments for hypertension, chronic kidney disease, and related conditions driven by dysregulated aldosterone. In its third-quarter 2024 earnings report, Mineralys Therapeutics highlighted key advancements in its clinical trials and fi

TipRanks last month

MLYS
+4.31%
Q3 2024 Mineralys Therapeutics Inc Earnings Call

Q3 2024 Mineralys Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

MLYS
+4.31%
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biophar

GlobeNewswire last month

MLYS
+4.31%
Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation Conference:Date:Tuesday, November 12, 2024Time:4:00pm ESTFormat:Fireside ChatWeb

GlobeNewswire last month

MLYS
+4.31%
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-912

GlobeNewswire last month

MLYS
+4.31%
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular dis

GlobeNewswire last month

MLYS
+4.31%
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here. The event will feature comments

GlobeNewswire last month

MLYS
+4.31%
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 2 months ago

MLYS
+4.31%
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases dr

GlobeNewswire 2 months ago

MLYS
+4.31%
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Wells Fargo Healthcare Conference, being held in Boston, MA on September 4-6, 2024. Wells Fargo Healthcare ConferenceDate:Time:Format:Webcast Lin

GlobeNewswire 3 months ago

MLYS
+4.31%
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 – – Ongoing Explore-CKD Phase 2 trial is ramping up enrollment under the amended protocol and is anticipated to deliver topline data in 1H 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, In

GlobeNewswire 4 months ago

MLYS
+4.31%
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the second quarter ended June 30, 2024, after the financial markets close on Tuesday, August 13, 2024. Tuesday, August 13th @ 4:30 p.m. ETDomestic:1-877-407-9127Intern

GlobeNewswire 4 months ago

MLYS
+4.31%
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares

Mineralys Therapeutics Inc is focused on developing targeted therapies for cardiovascular and cardiorenal diseases. Over the past year, Jon Congleton has sold a total of 137,856 shares and purchased 10,750 shares of Mineralys Therapeutics Inc. The insider transaction history at Mineralys Therapeutics Inc shows a pattern of insider activity.

GuruFocus.com 5 months ago

MLYS
+4.31%
Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares

On July 11, 2024, Adam Levy, the Chief Financial Officer and Secretary of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a sale of 10,757 shares of the company. Following this transaction, the insider now owns 247,611 shares of Mineralys Therapeutics Inc. Mineralys Therapeutics Inc is focused on developing targeted therapies for cardiovascular and kidney diseases.

GuruFocus.com 5 months ago

MLYS
+4.31%
Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)

On June 20, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a significant transaction by selling 49,313 shares of the company. Following this sale, the insider now owns 926,958 shares of Mineralys Therapeutics Inc. Mineralys Therapeutics Inc is focused on developing targeted therapies for cardiovascular and kidney diseases.

GuruFocus.com 5 months ago

MLYS
+4.31%
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares

On June 14, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a sale of 72,797 shares of the company, according to the SEC Filing.

GuruFocus.com 6 months ago

MLYS
+4.31%
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that Alexander M. Gold, M.D. has been appointed to the Company's Board of Directors (the Board), effective June 13, 2024. “We are delighte

GlobeNewswire 6 months ago

MLYS
+4.31%
Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)

On June 11, 2024, Adam Levy, the Chief Financial Officer and Secretary of Mineralys Therapeutics Inc (NASDAQ:MLYS), sold 96,815 shares of the company.

GuruFocus.com 6 months ago

MLYS
+4.31%
Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, FL on June 10-13, 2024. Goldman Sachs 45th Annual Global Healthcare

GlobeNewswire 6 months ago

MLYS
+4.31%
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript May 11, 2024 Mineralys Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Mineralys First Quarter 2024 Earnings Conference Call. At […]

Insider Monkey 7 months ago

MLYS
+4.31%

Performance Overview

Return	MLYS	S&P 500
YTD	+43.49%	+24.34%
1-Year	+54.25%	+24.38%
3-Year	-41.52%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics Announces Q3 2024 Results and Updates

Q3 2024 Mineralys Therapeutics Inc Earnings Call

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares

Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares

Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript

Performance Overview